GH Research (NASDAQ:GHRS - Free Report) had its price objective trimmed by Canaccord Genuity Group from $31.00 to $28.00 in a research note released on Monday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.
GHRS has been the topic of several other reports. HC Wainwright reissued a "buy" rating and issued a $40.00 target price on shares of GH Research in a research report on Thursday, September 5th. JMP Securities reaffirmed a "market outperform" rating and set a $39.00 price target on shares of GH Research in a research report on Wednesday, September 4th.
View Our Latest Research Report on GH Research
GH Research Stock Performance
Shares of NASDAQ GHRS traded up $0.38 during mid-day trading on Monday, hitting $9.47. The stock had a trading volume of 159,750 shares, compared to its average volume of 79,965. The company has a 50 day moving average of $7.76 and a two-hundred day moving average of $10.36. GH Research has a twelve month low of $5.05 and a twelve month high of $14.99. The firm has a market cap of $492.72 million, a PE ratio of -12.10 and a beta of 0.74.
GH Research (NASDAQ:GHRS - Get Free Report) last released its earnings results on Tuesday, September 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.03. Equities research analysts predict that GH Research will post -0.85 EPS for the current fiscal year.
Institutional Investors Weigh In On GH Research
A hedge fund recently raised its stake in GH Research stock. Lynx1 Capital Management LP lifted its position in shares of GH Research PLC (NASDAQ:GHRS - Free Report) by 80.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,310,563 shares of the company's stock after acquiring an additional 1,471,946 shares during the quarter. GH Research accounts for approximately 9.1% of Lynx1 Capital Management LP's investment portfolio, making the stock its 6th biggest holding. Lynx1 Capital Management LP owned approximately 6.36% of GH Research worth $35,291,000 at the end of the most recent quarter. Institutional investors own 56.90% of the company's stock.
About GH Research
(
Get Free Report)
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
Featured Articles
Before you consider GH Research, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GH Research wasn't on the list.
While GH Research currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
